To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
-
Publication number: 20130023428Abstract: Methods and kits for identifying and/or monitoring neurological conditions in a patient using ratios of biomarkers are disclosed. The neurological conditions may include, for example, Alzheimer's disease or mild cognitive impairment. The particular biomarkers that may be useful in identifying and/or monitoring neurological conditions may include, for example, biliverdin reductase, biliverdin reductase, estrogen receptor alpha, superoxide dismutase, S100A7, hemeoxygenase 1, matrix metalloproteinase 9 and platelet derived growth factor receptor. In particular, ratios of these biomarkers are useful.Type: ApplicationFiled: September 2, 2010Publication date: January 24, 2013Inventors: Claudius Mueller, Matthew Schrag, Lance Liotta, Wolff M. Kirsch, Harry V. Vinters
-
Publication number: 20130017550Abstract: Methods for identifying a therapeutic agent for treating a Germinal Center Kinase (GCK)-Like Kinase (GLK)-mediated disease are disclosed. Methods for detecting a modulation of GLK signaling by a lest compound are disclosed. Also disclosed are methods for detecting the presence and/or severity of an autoimmune disease and/or cancer.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Applicant: NATIONAL HEALTH RESEARCH INSTITUTESInventors: Tse-Hua TAN, Huai-Chia Chuang
-
Publication number: 20130017204Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: ApplicationFiled: July 19, 2012Publication date: January 17, 2013Applicants: THE BOARD OF REGENTS OF UNIVERSITY OF OKLAHOMA, NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Lauren O. Bakaletz, Robert S. Munson, JR., David W. Dyer
-
Publication number: 20130017546Abstract: Newly identified proteins as markers for the detection of breast tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, as well as methods for tumor diagnosis and therapy using such ligands.Type: ApplicationFiled: October 26, 2010Publication date: January 17, 2013Applicant: Externautics S.P.A.Inventors: Renata Grifantini, Piero Pileri, Susanna Campagnoli, Alberto Grandi, Matteo Parri, Andrea Pierleoni, Renzo Nogarotto
-
Publication number: 20130017556Abstract: The invention relates to methods, compositions and kits for detecting molecular interactions. In one embodiment, the invention relates to methods for quantifying HDL interactions with biomolecules. In still another embodiment, the invention relates to methods for determining HDL function.Type: ApplicationFiled: April 16, 2012Publication date: January 17, 2013Inventor: Kirkwood A. Pritchard Jr., JR.
-
Publication number: 20130018060Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.Type: ApplicationFiled: September 12, 2012Publication date: January 17, 2013Applicant: Pharmacyclics, Inc.Inventors: Lee Honigberg, Eric Verner, Joseph J. Buggy, David J. Loury, Wei Chen
-
Publication number: 20130017558Abstract: The invention generally relates to isolated human or humanized antibodies or functional fragments thereof that include an antigen binding region that specifically binds a form of a disintegrin and metalloprotease 12 (ADAM12) present in a tissue or body fluid that is indicative of a cancer.Type: ApplicationFiled: July 26, 2012Publication date: January 17, 2013Inventor: Ulla M. Wewer
-
Publication number: 20130017557Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.Type: ApplicationFiled: December 8, 2009Publication date: January 17, 2013Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
-
Publication number: 20130012568Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.Type: ApplicationFiled: September 6, 2012Publication date: January 10, 2013Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, JR., Jeffrey Robert Erickson
-
Publication number: 20130011849Abstract: Methods and compositions are provided for detection of biological substances in nasal specimen.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Inventor: Robert I. Henkin
-
Publication number: 20130012519Abstract: A method of identifying cancer or an associated disorder comprising identifying and quantifying STAT3 occurring in a biological sample taken from a subject after administering a SFK inhibitor to said subject.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicants: BRISTOL-MYERS SQUIBB COMPANY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Faye M. Johnson, Nicholas J. Donato, Francis Y. Lee
-
Publication number: 20130011857Abstract: The invention relates to complement Factor H for use in the prevention and treatment of oxidative stress disease conditions in a patient, the use of Factor H in the preparation of a pharmaceutical preparation, and methods of determining the specific binding of Factor H to MDA and/or MAA in a sample.Type: ApplicationFiled: February 4, 2011Publication date: January 10, 2013Applicant: CEMM FORSCHUNGSZENTRUM FUR MOLEKULARE MEDIZIN GMBHInventors: Christoph Binder, David Weismann
-
Publication number: 20130004504Abstract: A method of affecting a multimeric protein comprising an equilibrium of assembly states, each assembly having a plurality of units, wherein each of the units comprises a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms under four conditions, wherein the method comprising: applying to the multimeric protein a composition comprising a compound adapted to affect formation of an active form of the multimeric protein; associating the composition with an active form of the multimeric protein; and promoting the multimeric protein to assemble into the active form, thereby affecting the multimeric protein to form the active form, wherein the multimeric protein is phenylalanine hydroxylase.Type: ApplicationFiled: June 29, 2012Publication date: January 3, 2013Applicant: Fox Chase Cancer CenterInventor: Eileen K. JAFFE
-
Publication number: 20130004964Abstract: Method and system for carrying out heterogeneous chemical or biological reactions are disclosed. The method comprising providing an analytical device having at least one liquid processing unit having at least one reaction chamber and a first inlet channel in fluid communication with the reaction chamber. The method further comprises supplying to the reaction chamber via the first inlet channel or a second inlet channel analyte capturing particles, supplying to the reaction chamber via the first inlet channel or the second inlet channel a liquid sample containing an analyte of interest, and confining by an equilibrium of forces the analyte capturing particles in a particle rearrangement zone within the reaction chamber. The forces comprise a drag force Fd generated by flowing liquids and a counter-oriented force Fg. The method also comprises capturing analytes present in the liquid sample with the particles in the particle rearrangement zone.Type: ApplicationFiled: March 2, 2012Publication date: January 3, 2013Applicant: Roche Diagnostics Operations,Inc.Inventors: Christoph Boehm, Brigitte Niederberger, Rijk Edwin Oosterbroek, Susanne Wuerl
-
Publication number: 20130004965Abstract: This invention provides methods of determining the number and percent of tissue specific stem cells (TSSCs) in a sample of cells, a population of cells or a sample of tissue. The methods rely on detecting the pattern-specific asymmetric localization of asymmetric self-renewal associated (ASRA) proteins or cell cycle specific proteins (CSSP) in cell undergoing asymmetrical self-renewal, which is a characteristic of TSSCs. The methods can be applied to any situations in which the percent of TSSC is desired such as laboratory research on adult stem cells, in drug development tests, prognostic indicator and therapeutic index, as a diagnostic and prognostic indicator and in monitoring TSSC expansion, e.g., in cell manufacturing processes.Type: ApplicationFiled: December 3, 2010Publication date: January 3, 2013Applicant: BOSTON BIOMEDICAL RESEARCH INSTITUTE, INC.Inventor: James L. Sherley
-
Publication number: 20130004963Abstract: The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: September 8, 2007Publication date: January 3, 2013Inventors: Peter Hornbeck, Judit Villen, Albrecht Moritz, John Rush, Steven Gygi, Sean Beausoleil, Scott Gerber
-
Publication number: 20130004521Abstract: Provided is a method of determining the level of resistance or sensitivity of cancer stem cells to a death receptor agonist. The method includes detecting the level of IAP in one or more DR5/DDX3/IAP complexes in or from the cancer stem cells. Also provided is a method of killing cancer stem cells in a subject and a method of reducing the risk of cancer recurrence in a subject.Type: ApplicationFiled: March 18, 2011Publication date: January 3, 2013Applicants: LOYOLA UNIVERSITY CHICAGO, THE UAB RESEARCH FOUNDATIONInventors: Donald J. Buchsbaum, Albert F. Lobuglio, Tong Zhou, Kimberly Foreman
-
Publication number: 20130007913Abstract: A eukaryotic input circuit: computationally designed receptors, synthetic eukaryotic signal transduction pathways, and a synthetic signal sensitive promoter that allow highly specific transcriptional induction in response to an externally provided ligand is disclosed. The input circuit is able to specifically bind a targeted substance and transmit a signal to the nucleus where transcription of a gene is activated. An output circuit serves as a simple readout system of the substance detected by the input circuit. The readout circuit exemplified here is a degreening circuit which causes plants to turn white. Activation of the degreening circuit can be detected by eye, or remotely with a variety of machines (hand-held, aircraft or satellite based) and is also resettable. When linked the input circuit if operably linked to the output circuit, produces a functional plant detector.Type: ApplicationFiled: April 2, 2012Publication date: January 3, 2013Inventors: June Medford, Mauricio S. Antunes
-
Publication number: 20130004509Abstract: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided.Type: ApplicationFiled: February 22, 2011Publication date: January 3, 2013Inventor: Levi Garraway
-
Patent number: 8343122Abstract: The invention provides for a urinary monitoring device to monitor for the presence or absence of markers indicative of a urinary tract infection (UTI). The invention also provides for methods of using such a device.Type: GrantFiled: April 23, 2010Date of Patent: January 1, 2013Inventor: Geoffrey H Gorres
-
Publication number: 20120328517Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.Type: ApplicationFiled: August 9, 2012Publication date: December 27, 2012Applicant: Dyax Corp.Inventors: William Markland, Robert C. Ladner
-
Publication number: 20120328599Abstract: The present invention provides moieties that bind to the asymmetric contact interface of a receptor tyrosine kinase (RTK), wherein the moieties inhibit ligand induced trans autophosphorylation of the RTK. The present invention also provides methods of treating or preventing an RTK-associated disease and methods for identifying moieties that bind to an asymmetric contact interface of an RTK.Type: ApplicationFiled: January 13, 2011Publication date: December 27, 2012Applicant: YALE UNIVERSITYInventors: Jae Hyun Bae, Irit Lax, Joseph Schlessinger
-
Publication number: 20120328528Abstract: [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. [MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of SEQ ID NO: 1, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.Type: ApplicationFiled: March 8, 2011Publication date: December 27, 2012Applicant: FUJIFILM CORPORATIONInventors: Sumio Sugano, Yukari Kanzaki, Tsuneo Saga, Atsushi Tsuji
-
Publication number: 20120329071Abstract: The present invention relates to a method of diagnosing a renal disorder. The method includes the steps of: (1) obtaining a biological sample from a subject; and (2) determining, in the biological sample, a level of one or more proteins whose abundance in urine change due to the renal disorder, wherein an increase or decrease in the level of one or more of the proteins compared to a control level is indicative of a renal disorder.Type: ApplicationFiled: March 7, 2011Publication date: December 27, 2012Inventors: Mark Chance, Daniella Schlatzer
-
Publication number: 20120329760Abstract: Methods of identifying a subject having a urinary tract infection using RNase 7 are described. The methods include providing a test sample of urine from the subject, determining the level of RNase 7 in the test sample, and then comparing the level of RNase 7 in the test sample to the level of RNase 7 in a control. A higher level of RNase 7 in the test sample indicates that the subject has an acute urinary tract infection, whereas a lower level of RNase 7 in the test sample indicates that the subject only has a chronic urinary tract infection.Type: ApplicationFiled: April 19, 2012Publication date: December 27, 2012Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: David Hains, Andrew Lawrence Schwaderer, John David Spenser
-
Publication number: 20120329070Abstract: Methods and kits are provided for assessing radiation injury and exposure in a subject. The methods comprise measuring the levels of at least two (2) protein biomarkers from different biological pathways and correlating the levels with an assessment of radiation injury and exposure. Additional use of peripheral blood cell counts and serum enzyme biomarkers, evaluated in the early time frame after a suspected radiation exposure, and use of integrated multiple parameter triage tools to enhance radiation exposure discrimination and assessment are also provided. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the subject, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis.Type: ApplicationFiled: June 12, 2007Publication date: December 27, 2012Inventors: William Blakely, Natalia Ossetrova, Marcy Grace, Alexandra Miller, Jean M. Muderhwa, Glen Manglapus
-
Publication number: 20120329854Abstract: The present invention provides in vitro methods for detecting, grading or prognosticating cancer, in particular prostate cancer. The invention further provides isolated polynucleotides suitable for reducing or inhibiting the expression of protein kinase C beta I and/or II and/or alpha (and consequently the levels of histone H3 phosphorylated at threonine 6, histone H3 monomethylated at lysine 4, histone H3 dimethylated at lysine 4, histone H3 trimethylated at lysine 4) and further relates to pharmaceutical compositions comprising said polynucleotides for the treatment or prevention of cancer, in particular prostate cancer.Type: ApplicationFiled: August 3, 2010Publication date: December 27, 2012Applicant: UNIVERSITÄTSKLINIKUM FREIBURGInventors: Eric Metzger, Roland Schüle
-
Publication number: 20120321615Abstract: Disclosed herein is a method for predicting the prognosis, the likelihood of metastasis in, or the desirability of administering an aggressive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation of one or more of certain proteins compared to a positive and/or negative reference standard; or the total amount of COX-2 protein compared to a positive and/or negative reference standard. Also described are methods for treating subjects likely to develop metastatic colorectal carcinoma, and pharmaceutical compositions and kits for implementing the methods of the invention.Type: ApplicationFiled: May 25, 2012Publication date: December 20, 2012Inventors: Emanuel Petricoin, III, Lance A. Liotta, Mariaelena Pierobon, Valerie Calvert
-
Publication number: 20120322062Abstract: The invention is directed to methods of detecting Cowden syndrome (CS) or CS-like syndrome in an individual or determining whether an individual is at risk for developing Cowden syndrome (CS) or CS-like syndrome comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is positive for, or at risk of developing, CS or CS-like syndrome. The invention is also directed to an article of manufacture for detecting Cowden syndrome (CS) or Cowden-like syndrome in an individual, comprising one or more agents that detects mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, and instructions for use.Type: ApplicationFiled: April 12, 2012Publication date: December 20, 2012Applicant: The Cleveland Clinic FoundationInventor: Charis Eng
-
Publication number: 20120322080Abstract: The present invention relates to a method of detecting the presence of cancer by measuring the level of enzyme activity and autoantibodies in the blood of an individual. In particular the present invention relates to methods for measurement of activated cAMP-dependent protein kinase A (PKA) activity and antibodies to PKA, a kit for activated PKA activity measurement, and the use of the measured levels of these analytes for determining the presence of cancer.Type: ApplicationFiled: October 14, 2010Publication date: December 20, 2012Applicant: TRAXXSSON, LLCInventors: Robert Puskas, Douglas Held
-
Publication number: 20120322683Abstract: An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte.Type: ApplicationFiled: July 6, 2012Publication date: December 20, 2012Inventors: David J. Liu, Kai Wu, Xing Su
-
Publication number: 20120322081Abstract: Provided herein is a large immuno-sorbent surface area assay (ALISSA) for rapid and sensitive detection of toxin or enzyme activity. This assay is designed to capture a low number of toxin or enzyme molecules and to measure their intrinsic protease activity via conversion of a fluorigenic or luminescent substrate. The ALISSA is significantly faster and more sensitive than methods routinely utilized in the art. This assay is applicable for use for detection of a variety of toxins or enzymes having proteolytic activity, such as botulinum neurotoxin, bacillus anthracis lethal factor, human chitinases, and aspergillus fumigatus proteases. Also provided are methods for constructing and identifying novel luminescent or fluorescent substrates suitable for use with the ALISSA method.Type: ApplicationFiled: November 29, 2011Publication date: December 20, 2012Inventors: Markus Kalkum, Karine Bagramyan
-
Publication number: 20120324593Abstract: Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions, and animal models of conditions associated with a loss of elastic fibers.Type: ApplicationFiled: April 12, 2012Publication date: December 20, 2012Applicant: MASSACHUSETTS EYE & EAR INFIRMARYInventors: Tiansen Li, Xiaoqing Liu
-
Publication number: 20120322074Abstract: Newly identified proteins as markers for the detection of prostate tumors, or as targets for their therapeutic treatment, affinity ligands capable of selectively interacting with said markers as well as methods for tumor diagnosis and therapy using the same.Type: ApplicationFiled: October 26, 2010Publication date: December 20, 2012Applicant: EXTERNAUTICS S.P.A.Inventors: Renata Grifantini, Piero Pileri, Susanna Campagnoli, Alberto Grandi, Matteo Parri, Andrea Pierleoni, Renzo Nogarotto
-
Publication number: 20120321609Abstract: A method of desensitizing 5-HT2R signaling in the mammal is provided. The method comprises one or more of: 1) inhibiting CRFR1 activation of 5-HT2AR signaling by preventing trafficking of intracellular vesicles or blocking recycling of 5-HT2AR to the cell surface; 2) blocking PDZ binding motifs in the carboxyl-terminal tail domains of at least one of CRFR1, 5-HT2AR or 5-HT2CR; or 3) blocking the interaction of a 5-HT2R or a CRFR1 with a PDZ-domain-containing protein selected from the group consisting of MAGI-1 PDZ1, MAGI-2 PDZ1, MAGI-3 PDZ1, PSD95 PDZ 1&2, PSD95 PDZ3, CAL PDZ, SAP97 PDZ 1&2, PTPN13 PDZ 4&5, PDZK2 PDZ1, MPP3 PDZ, ERBIN PDZ and MUPP1 PDZ 12.Type: ApplicationFiled: April 11, 2012Publication date: December 20, 2012Inventors: Stephen Ferguson, Ana Magalhaes, Hymie Anisman
-
Publication number: 20120321628Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.Type: ApplicationFiled: June 8, 2012Publication date: December 20, 2012Applicant: Genentech, Inc.Inventors: Ralph H. Schwall, Kelly H. Tabor
-
Publication number: 20120316187Abstract: The invention relates to a method for predicting the response to the treatment with an EGFR tyrosine kinase inhibitor of a patient suffering lung cancer an carrying a mutation in the EGFR gene based on the expression levels in a sample of said patient of the BRCA1 gene wherein low BRCA1 expression levels are indicative of a positive response of a patient. This positive response is also observed in patients showing the T790M mutation in the EGFR gene which is usually associated with resistance to EGFR tyrosine kinase inhibitors.Type: ApplicationFiled: November 15, 2010Publication date: December 13, 2012Applicant: PANGAEA BIOTECH, S.L.Inventors: Rafael Rosell Costa, Miguel Tarón Roca
-
Publication number: 20120315650Abstract: The present invention relates to methods and means for detecting ADAMTS13 immune complexes in a sample. The methods include the steps of capturing and labelling immune complexes of anti-ADAMTS13 antibodies. Capturing and labelling may be achieved by two different binding units targeting the immune complexes. The invention further relates to diagnosing diseases associated with immunologic ADAMTS13 dysfunction like TTP (thrombotic thrombocytopenic purpura).Type: ApplicationFiled: May 18, 2012Publication date: December 13, 2012Applicants: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Silvia Ferrari, Bernadette Gruber, Barbara Plaimauer, Hanspeter Rottensteiner, Friedrich Scheiflinger
-
Publication number: 20120315629Abstract: Described are cell surface and circulating markers for aging related disorders (specific isoforms of NADH oxidase (arNOX)). Recombinant age-related NADH oxidase isoforms and their coding sequences and methods for detecting arNOX isoform presence and quantitation in tissues and in blood, sera, urine, saliva, perspiration and in other body fluids, are provided. Recombinant arNOX proteins are useful in preparing antigens for use in the generation of monoclonal and polyclonal antibodies as well as immunogenic compositions for diagnosis and treatment of aging disorders. DNA probes based on the DNA sequence information provide may be used to identify individuals at risk for aging disorders and for development of therapeutic interventions or anti-aging cosmetic or other formulations of benefit in slowing the aging process in mammals.Type: ApplicationFiled: August 17, 2010Publication date: December 13, 2012Applicant: Nox Technologies ,Inc.Inventors: D. James Morre, Xiaoyu Tang, Sara Dick, Christiaan Meadows, Dorothy M. Morre
-
Publication number: 20120315281Abstract: Methods for the treatment of renal injury include the use of arginase inhibitors in the treatment and prevention of diabetic nephropathy, albuminuria and azotemia amongst others, and methods for identifying agents for the treatment of renal injury.Type: ApplicationFiled: May 11, 2012Publication date: December 13, 2012Applicant: THE PENN STATE RESEARCH FOUNDATIONInventor: Alaa S. AWAD
-
Publication number: 20120315630Abstract: The invention provides novel biomarkers, kits, and methods of diagnosing, prognosing, and subtyping IBS. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of novel IBS biomarkers identified herein.Type: ApplicationFiled: April 6, 2012Publication date: December 13, 2012Applicant: Prometheus Laboratories Inc.Inventors: Hua Gong, Shui Long Wang, Sharat Singh
-
Publication number: 20120315649Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 10B, Cadherin-16, Caspase-9, Bcl2 antagonist of cell death, Caspase-1, Cadherin-1, Poly [ADP-ribose] polymerase 1, Cyclin-dependent kinase inhibitor 1, Cadherin-5, Myoglobin, Apolipoprotein A-II, Mucin-16, Carcinoembryonic antigen-related cell adhesion molecule 5, and Cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries.Type: ApplicationFiled: August 27, 2010Publication date: December 13, 2012Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20120309020Abstract: The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) polypeptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided.Type: ApplicationFiled: June 1, 2012Publication date: December 6, 2012Applicant: Gilead Biologics, Inc.Inventors: Victoria Smith, Joanne I. Adamkewicz, Susan K. Lyman, Jason Chien, Xiaoming Li, Lixin Shao, Jeffrey D. Bornstein
-
Publication number: 20120308479Abstract: To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.Type: ApplicationFiled: July 9, 2012Publication date: December 6, 2012Applicants: THE JOHNS HOPKINS UNIVERSITY, GENZYME CORPORATIONInventors: Stephen MADDEN, Clarence WANG, Brian P. COOK, John LATERRA, Kevin WALTER
-
Publication number: 20120309019Abstract: Provided herein is a method for detecting the presence of a unique subset of unhealthy bone marrow-derived cell (BMDC) by co-staining the cytoplasmic and/or nuclear expression of PDPK FA/GSK-3?, and specific BMDC markers as the diagnostic indicator for disease predispositions from very early-stage aberrant wound healing, chronic inflammations, immune disorder towards end-stage fibrotic disease and neoplasia in cancer-free human subjects.Type: ApplicationFiled: November 1, 2011Publication date: December 6, 2012Applicant: NATIONAL TSING HUA UNIVESITYInventor: Shiaw-Der YANG
-
Publication number: 20120309018Abstract: Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided.Type: ApplicationFiled: June 6, 2011Publication date: December 6, 2012Applicant: Myriad Genetics, IncorporatedInventors: Mark Skolnick, Jerry Lanchbury, Kirsten Timms, Chris Neff, Ryan Hoff, Hubert Wang, Susanne Wagner, Zaina Sangale
-
Publication number: 20120309021Abstract: The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.Type: ApplicationFiled: June 6, 2012Publication date: December 6, 2012Applicant: BAXTER INTERNATIONAL INC.Inventors: Christian Lubich, Juergen Siekmann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
-
Publication number: 20120308570Abstract: The present invention relates to methods of modulating the level of inducible nitric oxide synthase (iNOS) in a cell which comprises administering to the cell a compound which modulates binding of SPRY domain-containing SOCS box protein (SSB) to iNOS, and/or a compound which modulates SSB activity in the cell. Further provided are methods of treating or preventing disease in a subject by modulating the level of iNOS in a cell, as well as compounds which modulate binding of SSB to iNOS and compounds which modulate SSB activity.Type: ApplicationFiled: May 6, 2010Publication date: December 6, 2012Inventors: Tatiana Kolesnik, Zhihe Kuang, Rowena Sue Lewis, Sandra Elaine Nicholson, Ray Norton
-
Patent number: 8323943Abstract: The screening method for an anticancer drug comprises selecting a compound which blocks the kinase activity of TNIK, or blocks the combination of TNIK with ?-catenin/TC4 transcription complex.Type: GrantFiled: August 13, 2008Date of Patent: December 4, 2012Assignee: National Cancer CenterInventors: Tesshi Yamada, Miki Shitashige, Setsuo Hirohashi
-
Patent number: 8323913Abstract: Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.Type: GrantFiled: May 9, 2011Date of Patent: December 4, 2012Assignee: Mayo Foundation for Medical Education and ResearchInventors: Cheryl A. Conover, Antonio Bayes-Genis, David R. Holmes, Robert S. Schwartz